Alterity Therapeutics Ltd. (AU:ATH)
ASX:ATH
Want to see AU:ATH full AI Analyst Report?
ATH Stock Chart & Stats
AU$0.01
>-AU$0.01(-10.00%)
At close: 4:00 PM EST
AU$0.01
>-AU$0.01(-10.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume25.42M
Average Volume (3M)16.33M
Market Cap
AU$4.89B
Enterprise ValueAU$48.84M
Total Cash (Recent Filing)AU$49.20M
Total Debt (Recent Filing)AU$163.91K
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding10,875,416,000
10 Day Avg. Volume24,202,939
30 Day Avg. Volume16,327,471
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.51
Price to Sales (P/S)11.76
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.01Price Target Upside0.00%
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$3.30M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA 46.03% top-line increase indicates meaningful commercial or grant progress and supports continued R&D investment. Sustained revenue expansion over quarters can improve trial funding options, increase partner interest, and reduce sole reliance on dilutive financing over the medium term.
Very Low LeverageExtremely low debt reduces financial distress risk and preserves balance sheet flexibility. For a clinical‑stage biotech, minimal leverage lowers bankruptcy risk during lengthy trials and makes the company more attractive for partnerships or milestone financing without high fixed interest obligations.
Proprietary Lead ProgramsOwnership of small‑molecule, iron‑modulating compounds and focus on MSA represent a clear scientific differentiation and intellectual property basis. A disease‑modifying approach in a high unmet‑need neurodegenerative area supports durable strategic value and potential for licensing or acquisition.
Bears Say
Persistent Negative MarginsConsistent negative EBIT and net margins show the company is not generating operational profits. For a clinical‑stage biotech with long development timelines, sustained losses erode equity and raise dilution risk, constraining the firm's ability to self‑fund later‑stage trials.
Weak Cash GenerationNegative operating and free cash flow with sharply declining FCF growth indicate poor conversion of activities into liquidity. This reduces runway, increases reliance on external funding, and can force hurried financing or unfavorable partner terms, impeding long‑term program execution.
No Recurring Product RevenueAbsence of commercialized products means operations depend on periodic equity or financing rounds. That reliance raises dilution and financing execution risk, and without recurring revenues or sizable partnership inflows the company faces structural funding pressure throughout multi‑year clinical development.
Alterity Therapeutics News
ATH FAQ
What was Alterity Therapeutics Ltd.’s price range in the past 12 months?
Alterity Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Alterity Therapeutics Ltd.’s market cap?
Alterity Therapeutics Ltd.’s market cap is AU$4.89B.
When is Alterity Therapeutics Ltd.’s upcoming earnings report date?
Alterity Therapeutics Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 274 days.
How were Alterity Therapeutics Ltd.’s earnings last quarter?
Alterity Therapeutics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.045 earnings per share for the quarter, missing the consensus estimate of -AU$0.029 by -AU$0.016.
Is Alterity Therapeutics Ltd. overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently same.
Does Alterity Therapeutics Ltd. pay dividends?
Alterity Therapeutics Ltd. does not currently pay dividends.
What is Alterity Therapeutics Ltd.’s EPS estimate?
Alterity Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd. have?
Alterity Therapeutics Ltd. has 10,875,416,000 shares outstanding.
What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?
Alterity Therapeutics Ltd. reported an EPS of -AU$0.045 in its last earnings report, missing expectations of -AU$0.029. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.01 (0.00% )
AU$0.01 (0.00% )
Blogger Sentiment
Bullish
AU:ATH Sentiment 96%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-30.19%
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd.
Alterity Therapeutics (ATH) is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, primarily targeting conditions such as Parkinson's disease and Alzheimer's disease. The company leverages its proprietary drug discovery platform to identify and develop small molecule therapies aimed at modifying disease progression and improving patient outcomes. Alterity is dedicated to advancing its clinical programs and expanding its pipeline of novel treatments to address significant unmet medical needs in the neurology sector.
ATH Stock 12 Month Forecast
Average Price Target
AU$0.01
▲(0.00% Upside)
Technical Analysis
Actinogen Medical
―
Cynata Therapeutics Limited
―
Tryptamine Therapeutics
―
Living Cell Technologies
―
Neuren Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---